Drug Resistance Collection

Antibiotic testing F006 / 9823
Antibiotic testing

Antibiotic testing F006 / 9822
Antibiotic testing

Antibiotic testing F006 / 9821
Antibiotic testing

Antibiotic testing F006 / 9820
Antibiotic testing

Antibiotic testing F006 / 9819
Antibiotic testing

Multidrug efflux pump molecule F006 / 9748
Multidrug efflux pump. Molecular model of the multidrug efflux pump AcrB from the bacterium Escherichia coli transporting two doxorubicin molecules

Transcription activator and DNA F006 / 9721
Transcription activator and DNA. Molecular model of the transcriptional activator of the multidrug efflux transporter BmrR bound to a molecule of DNA (deoxyribonucleic acid, red and blue)

NpmA methyltransferase F006 / 9707
NpmA methyltransferase, molecular model. Methyltransferase enzymes act to add methyl groups to nucleic acids such as DNA (deoxyribonucleic acid), a process called DNA methylation

Multidrug transporter molecule F006 / 9627
Multidrug transporter. Molecular model of the multidrug transporter Sav1866 from the bacterium Escherichia coli. This protein pumps drugs, including antibiotics, out of the bacterial cell

Multidrug transporter molecule F006 / 9596
Multidrug transporter. Molecular model of the multidrug transporter EmrD from the bacterium Escherichia coli. This protein pumps drugs, including antibiotics, out of the bacterial cell

Antibiotic resistance enzyme molecule F006 / 9405
Antibiotic resistance enzyme. Molecular model of an aminoglycoside phosphotransferase enzyme. This enzyme confers resistance to aminoglycoside antibiotics

Multidrug efflux pump molecule F006 / 9376
Multidrug efflux pump. Molecular model of the multidrug efflux pump AcrB from the bacterium Escherichia coli. This protein pumps drugs, including antibiotics, out of the bacterial cell

Bleomycin hydrolase molecule F006 / 9265
Bleomycin hydrolase. Molecular model of the cysteine protease bleomycin hydrolase. This enzyme is thought to be a major cause of resistance to the bleomycin chemotherapy drug

Nilotinib drug, molecular model. Nilotinib is a drug used for the treatment of chronic myelogenous leukemia (CML), a cancer of the blood

GNF-2 kinase inhibitor, molecular model. GNF-2 is used to help anti-cancer drugs overcome drug-resistant mutations. It is a selective allosteric BCR-ABL inhibitor that affects the tyrosine kinase

Bacterial pattern in petri dish C018 / 0305
Bacterial pattern in petri dish. Macrophotograph of a coloured pattern of Paenibacillus bacteria growing in a culture in a petri dish. This is a tip-splitting morphotype (T-type)

Drug Resistance, computer artwork
Conceptual computer artwork showing the virtual brick wall resistance of some pathogens to drugs. Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial or an

Drug Resistant Microbes, computer artwork
Conceptual computer illustration of a drug capsule being pushed aside by microbes that have developed an immunity to the drug

Imipenem antibiotic drug molecule
Imipenem antibiotic drug molecular model. Imipenem belongs to the carbapenem group of antibiotics. Bacteria are becoming increasingly resistant to carbapenems due to the bacterial enzyme NDM-1

S. maltophilia bacterium, TEM
Stenotrophomonas maltophilia bacterium, coloured transmission electron micrograph (TEM). This aerobic Gram-negative bacterium, previously known as Pseudomonas maltophilia

S. maltophilia bacteria, TEM
Stenotrophomonas maltophilia bacteria, coloured transmission electron micrograph (TEM). This aerobic Gram-negative bacterium, previously known as Pseudomonas maltophilia

Clostridium difficile bacteria, TEM
Clostridium difficile drug-resistant bacteria, coloured transmission electron micrograph (TEM). This bacterium, also known as C. diff, is a normal member of the intestinal flora in humans

Tigecycline molecule, MRSA antibiotic
Tigecycline molecule. Computer model of a molecule of the MRSA antibiotic drug tigecycline (brand name Tygacil, chemical formula C29.H39.N5.O8)

All Professionally Made to Order for Quick Shipping

"Unmasking the Battle: Unveiling Drug Resistance in Antibiotic Testing" In a race against time, scientists delve into the intricate world of drug resistance. The captivating images from Antibiotic testing F006/9823 to F006/9376 reveal the relentless fight against this silent enemy. Within these snapshots lies a story of resilience and adaptation. Antibiotic testing F006/9823 showcases the determination to find new solutions as researchers tirelessly explore potential treatments. Each test represents a step closer to unraveling the mystery behind drug resistance. Multidrug efflux pump molecule F006/9748 emerges as a key player, illustrating how bacteria can expel antibiotics before they have a chance to take effect. This molecular marvel acts as an obstacle that challenges medical advancements. Transcription activator and DNA F006/9721 provide insight into how genetic mutations contribute to antibiotic resistance. These complex interactions shed light on why some medications lose their effectiveness over time. NpmA methyltransferase F006/9707 reveals another layer of complexity, showcasing enzymes that modify antibiotics, rendering them useless against resistant strains, and is through understanding such mechanisms that we can develop strategies to combat this growing threat. The presence of multidrug transporter molecules (F006/9627 and F006/9596) further highlights nature's ability to adapt swiftly. These transporters act like gatekeepers, preventing drugs from reaching their intended targets within bacterial cells. Antibiotic resistance enzyme molecule (F006 / 9405) serves as a stark reminder of the urgent need for innovative approaches in medicine. Its existence underscores the importance of developing alternative therapies capable of bypassing or neutralizing these formidable adversaries. As we navigate this battle against drug resistance, it becomes clear that collaboration between scientists, healthcare professionals, and policymakers is crucial for success. Together, we must unlock new avenues for treatment while promoting responsible antibiotic use worldwide.